The University of Chicago Header Logo

Connection

Thomas F. Gajewski to Administration, Oral

Back to Details
This is a "connection" page, showing publications Thomas F. Gajewski has written about Administration, Oral.
Thomas F. Gajewski
Connection Strength
0.209
Administration, Oral
  1. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. Clin Cancer Res. 2017 07 01; 23(13):3269-3276.
    View in: PubMed
    Score: 0.126
  2. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 01; 22(23):4816-22.
    View in: PubMed
    Score: 0.054
  3. A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma. Invest New Drugs. 2016 Apr; 34(2):231-5.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.